Cellular Senescence in Non-Small Cell Lung Cancer
© 2023 The Author(s). Published by IMR Press..
Lung cancer has the highest mortality rate amongst all malignancies worldwide, and is the second-highest incidence of cancer in women. Non-small cell lung cancer (NSCLC) is responsible for approximately 80% of lung cancer cases. Recent studies indicate that cellular senescence may be a promising cancer biomarker. However, the regulation of cellular senescence and its underlying mechanisms in NSCLC are not yet fully understood. Here, we present a comprehensive analysis of the genes linked to cellular senescence in NSCLC. We also describe the secretory phenotype associated with NSCLC and examine its immune profile and prognostic potential. Our findings offer novel insights into the development of effective NSCLC treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Frontiers in bioscience (Landmark edition) - 28(2023), 12 vom: 28. Dez., Seite 357 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Huangkai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cellular senescence |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 20.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.31083/j.fbl2812357 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366703536 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366703536 | ||
| 003 | DE-627 | ||
| 005 | 20240222091613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.31083/j.fbl2812357 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM366703536 | ||
| 035 | |a (NLM)38179738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Huangkai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cellular Senescence in Non-Small Cell Lung Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Author(s). Published by IMR Press. | ||
| 520 | |a Lung cancer has the highest mortality rate amongst all malignancies worldwide, and is the second-highest incidence of cancer in women. Non-small cell lung cancer (NSCLC) is responsible for approximately 80% of lung cancer cases. Recent studies indicate that cellular senescence may be a promising cancer biomarker. However, the regulation of cellular senescence and its underlying mechanisms in NSCLC are not yet fully understood. Here, we present a comprehensive analysis of the genes linked to cellular senescence in NSCLC. We also describe the secretory phenotype associated with NSCLC and examine its immune profile and prognostic potential. Our findings offer novel insights into the development of effective NSCLC treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a cellular senescence | |
| 650 | 4 | |a non-small cell lung cancer | |
| 700 | 1 | |a Sun, Jiaen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Chuntao |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Minglei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Guofang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in bioscience (Landmark edition) |d 2009 |g 28(2023), 12 vom: 28. Dez., Seite 357 |w (DE-627)NLM186959230 |x 2768-6698 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:12 |g day:28 |g month:12 |g pages:357 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.31083/j.fbl2812357 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 12 |b 28 |c 12 |h 357 | ||